Igor Klepikov*

Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, Professor, Retired, Renton, WA, USA.

Received: April 24, 2024; Published: June 19, 2024

Abstract

The discovery and use of antibiotics in the treatment of patients with inflammatory diseases was one of the greatest medical achievements of the last century, saving millions of lives. However, eight decades have passed since the practical use of these drugs and their interference with the normal balance of nature led to the gradual and steady development of persistent side effects that eclipsed previous achievements and became complex and serious problems. These consequences include the development of microflora resistance, which is becoming an increasingly common representative of the microbiota of healthy people, the dynamics and variability of the etiology of acute pneumonia, an increase in the proportion of viruses and fungi as causative agents of pneumonia, a decrease in the effectiveness of antibiotics and a reduction in their justified use. Of all the listed consequences of antimicrobial therapy, only the resistance of microorganisms attracts the attention of specialists due to the loss of their former effectiveness by these drugs. The reason for such a narrowly focused assessment is the deep didactic distortion of professional ideas under the influence of antibiotics, which is their most serious side effect and requires correction in the first place.

 Keywords: SARS-CoV-2; Acute Pneumonia (AP)

References

1. Gould K. "Antibiotics: from prehistory to the present day". Journal of Antimicrobial Chemotherapy 71.3 (2016): 572-575.
2. Fleming A. "On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to their Use in the Isolation of B. influenzæ". British Journal of Experimental Pathology 10.3 (1929): 226-236.
3. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin”. Nature 4 (1988): 677-678.
4. Fleming A. "The Nobel Prize in Physiology or Medicine 1945 - Penicillin: Nobel Lecture". NobelPrize.org (2020).
5. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 51 (1942): 386-389.
6. Antimicrobial resistance (2021).
7. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection7 (2020): P808-810.
8. B Beović., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy, dkaa326 (2020).
9. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing [published online ahead of print, 2020 May 2]”. Clinical Infectious Diseases (2020): ciaa 530.
10. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 75 (2020): 614-616.
11. Puzniak L., et al. “A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19”. BMC Infectious Diseases 21 (2021):
12. M J Enzler., et al. “Antimicrobial Prophylaxis in Adults”. Mayo Clinic Proceedings 86.7 (2022): 686-701.
13. Alsaeed OM., et al. “The Use of Antibiotics for the Prevention of Surgical Site Infections in Two Government Hospitals in Taif, Saudi Arabia: A Retrospective Study”. Cureus 14.7 (2022): e26731.
14. Larson E. "Community factors in the development of antibiotic resistance". Annual Review of Public Health 28.1 (2007): 435-4
15. Charles D. "Despite Pledges To Cut Back, Farms Are Still Using Antibiotics". NPR (2018).
16. Hoffman SJ., et al. “An international legal framework to address antimicrobial resistance". Bulletin of the World Health Organization 93.2 (2015):
17. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010):
18. Yu KT and Wyer PC. “Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia”. Annals of Emergency Medicine 51 (2008): 651-662.
19. Dellinger RP., et al. “Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012”. Critical Care Medicine 41.2 (2013): 580-637.
20. Noritomi DT., et al. “Implementation of a multifaceted sepsis education program in an emerging country setting: clinical outcomes and cost-effectiveness in a long-term follow-up study”. Intensive Care Medicine 40 (2014): 182-191.
21. J P Metlay., et al. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine 200.7 (2019): e45-e67.
22. Paula Peyrani., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine 13.2 (2019): 139-152.
23. Gadsby NJ and Musher DM. “The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures”. Clinical Microbiology Reviews 5 (2022): e00015-22.
24. Z Wu., et al. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention”. JAMA 323.13 (2020): 1239-1242.
25. Murad M and Martin JC. “Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages”. Nature Reviews of Immunology 20 (2020): 355-362.
26. Zhou B., et al. “COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations”. Journal of Medical Virology (2021): 1-
27. Revised global burden of disease 2002 estimates (2004).
28. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 86 (2008): 408-416.
29. Ruuskanen O., et al. “Viral pneumonia". Lancet9773 (2011): 1264-1275.
30. Visseaux B., et al. “Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016”. PLoS One 12.7 (2017):
31. Shah MM., et al. “Seasonality of common human coronaviruses, United States, 2014-2021”. Emergency Infectious Dissease 28.10 (2022): 1970-197
32. C Heneghan., et al. “Differentiating viral from bacterial pneumonia”. April 8, 2020. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response. University of Oxford (2020).
33. Kamat IS., et al. “Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis”. Clinical Infectious Diseases3 (2020): 538-542.
34. Kamat IS., et al. “Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis”. Clinical Infectious Diseases3 (2020): 538-542.
35. Lhommet C., et al. “Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmanory Medicine 20 (2020): 62.
36. Kyriazopoulou E., et al. “BioFire® FilmArray® pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial”. Infectious Diseases and Therapy 10 (2021): 1437-1449.
37. Montes-Andujar L., et al. “Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis”. Thorax (2021).
38. Cilloniz C., et al. “Management of pneumonia in critically ill patients”. BMJ 375 (2021): e065871.
39. Enne VI., et al. “Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study”. Thorax 77 (2022): 1220-1228.
40. Richards G., et al. “CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS”. Journal of Intensive Care Medicine 26.1 (2011): 34-40.
41. Singer M., et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”. JAMA 315.8 (2016): 801-8
42. I Klepikov. “The Didactics of Acute Lung Inflammation”. Cambridge Scholars Publishing (2022): 320.
43. Thillai M., et al. “Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19”. Thorax 76 (2021): 182-184.
44. W Dierckx., et al. “CT-derived measurements of pulmonary blood volume in small vessels and the need for supplemental oxygen in COVID-19 patients”. Journal of Applied Physiology 133.6 (2022): 1295-129
45. A Ceccato and A Torres. “Sepsis and community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 7.
46. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Disease 220 (2019): 1166-1171.
47. Lin CK., et al. “Serum vascular endothelial growth factor affects tissue fluid accumulation and is associated with deteriorating tissue perfusion and oxygenation in severe sepsis: a prospective observational study”. European Journal of Medical Research 28 (2023):
48. LO Gostin., et al. “The Origins of Covid-19 — Why It Matters (and Why It Doesn’t)”. The New England Journal of Medicine 388 (2023): 2305-2308.

Citation

Citation: Igor Klepikov. “The Heavy Legacy of the Antibiotic Era”.Acta Scientific Medical Sciences 8.7 (2024): 168-175.

Copyright

Copyright: © 2024 Igor Klepikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.